Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia
- PMID: 9466526
- DOI: 10.1086/514204
Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia
Abstract
Limulus antilipopolysaccharide factor (LALF) can neutralize bacterial endotoxin, but its ability to prevent mortality following prolonged endotoxemia is unknown. Mice were challenged with an LD50 dose of intraperitoneal E. coli lipopolysaccharide (LPS) and then received LALF at various times after administration of LPS. Survival at 72 h was significantly improved by the administration of LALF at 4, 10, and even 24 h after LPS (73%, 78%, and 65% survival, respectively, vs. 15% survival in controls). Following intravenous administration of LALF at either 10 or 24 h after LPS, plasma levels of biologically active LPS abruptly fell (> 1000-fold lower than pre-LALF levels). Plasma LALF concentrations fell much more gradually in LPS-treated mice (t1/2 = 120 min) than in control mice (t1/2 = 2.5 min). In conclusion, LALF markedly decreased plasma concentrations of biologically active LPS and protected mice from lethality even when LALF was not administered until long after the onset of continuous endotoxemia.
Similar articles
-
A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases.Clin Diagn Lab Immunol. 2000 Jul;7(4):669-75. doi: 10.1128/CDLI.7.4.669-675.2000. Clin Diagn Lab Immunol. 2000. PMID: 10882670 Free PMC article.
-
Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor.Infect Immun. 1992 Jun;60(6):2506-13. doi: 10.1128/iai.60.6.2506-2513.1992. Infect Immun. 1992. PMID: 1587618 Free PMC article.
-
Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock.J Infect Dis. 1992 Mar;165(3):494-500. doi: 10.1093/infdis/165.3.494. J Infect Dis. 1992. PMID: 1538154
-
Comparison of endotoxin antagonism of linear and cyclized peptides derived from limulus anti-lipopolysaccharide factor.Surg Infect (Larchmt). 2006 Feb;7(1):45-52. doi: 10.1089/sur.2006.7.45. Surg Infect (Larchmt). 2006. PMID: 16509785
-
Peptides with dual mode of action: Killing bacteria and preventing endotoxin-induced sepsis.Biochim Biophys Acta. 2016 May;1858(5):971-9. doi: 10.1016/j.bbamem.2016.01.011. Epub 2016 Jan 20. Biochim Biophys Acta. 2016. PMID: 26801369 Review.
Cited by
-
Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins.J Clin Invest. 2001 Aug;108(3):485-93. doi: 10.1172/JCI13139. J Clin Invest. 2001. PMID: 11489942 Free PMC article.
-
A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases.Clin Diagn Lab Immunol. 2000 Jul;7(4):669-75. doi: 10.1128/CDLI.7.4.669-675.2000. Clin Diagn Lab Immunol. 2000. PMID: 10882670 Free PMC article.
-
Protective Effects of Nobiletin Against Endotoxic Shock in Mice Through Inhibiting TNF-α, IL-6, and HMGB1 and Regulating NF-κB Pathway.Inflammation. 2016 Apr;39(2):786-97. doi: 10.1007/s10753-016-0307-5. Inflammation. 2016. PMID: 26846885
-
Capture of lipopolysaccharide (endotoxin) by the blood clot: a comparative study.PLoS One. 2013 Nov 25;8(11):e80192. doi: 10.1371/journal.pone.0080192. eCollection 2013. PLoS One. 2013. PMID: 24282521 Free PMC article.
-
Host Defense Proteins and Peptides with Lipopolysaccharide-Binding Activity from Marine Invertebrates and Their Therapeutic Potential in Gram-Negative Sepsis.Mar Drugs. 2023 Nov 7;21(11):581. doi: 10.3390/md21110581. Mar Drugs. 2023. PMID: 37999405 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical